Suyash Deodhar

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Hiv Infected Patients

Top Venues

Biotech (Basel (Switzerland))

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Shrey Kanvinde, Suyash Deodhar, Tanmay A Kulkarni, Chinmay M Jogdeo
Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis. Biotech (Basel (Switzerland)) 12 (2) (2023)
Shrey Kanvinde, Tanmay Kulkarni, Suyash Deodhar, Deep Bhattacharya, Aneesha Dasgupta
Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer. Biotech (Basel (Switzerland)) 11 (1) (2022)
Milica Markovic, Suyash Deodhar, Jatin Machhi, Pravin Yeapuri, Maamoon Saleh, Benson J Edagwa, Rodney Lee Mosley, Howard E Gendelman
Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics 14 (3) (2022)
Suyash Deodhar, Brady Sillman, Aditya N Bade, Sean N Avedissian, Anthony T Podany, JoEllyn M McMillan, Nagsen Gautam, Brandon Hanson, Bhagya L Dyavar Shetty, Adam Szlachetka, Morgan Johnston, Michellie Thurman, Daniel J Munt, Alekha K Dash, Milica Markovic, Arik Dahan, Yazen Alnouti, Alborz Yazdi, Bhavesh D Kevadiya, Siddappa N Byrareddy, Samuel M Cohen, Benson J Edagwa, Howard E Gendelman
Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nature communications 13 (1) (2022)
Denise A Cobb, Nathan Smith, Suyash Deodhar, Aditya N Bade, Nagsen Gautam, Bhagya Laxmi Dyavar Shetty, JoEllyn McMillan, Yazen Alnouti, Samuel M Cohen, Howard E Gendelman, Benson J Edagwa
Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nature communications 12 (1) (2021)